NDAORALTABLET
Approved
Apr 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
FOSAMAX PLUS D (alendronate sodium and cholecalciferol) by Merck & Co.. Approved for vitamin d [epc]. First approved in 2005.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FOSAMAX PLUS D is a fixed-dose combination oral tablet containing alendronate sodium (a bisphosphonate) and cholecalciferol (Vitamin D) approved for osteoporosis management. It works by inhibiting bone resorption via the bisphosphonate mechanism while supplementing Vitamin D to support bone health and calcium absorption. The combination targets patients requiring dual therapy for fracture risk reduction in postmenopausal women and men.
$0.604MPart D
LOE ApproachingDeclining
Product is in late-stage lifecycle with modest Medicare Part D utilization (1,890 claims in 2023), suggesting declining team infrastructure and reduced career growth opportunities on the brand.
Mechanism of Action
Pharmacologic Class:
Vitamin D
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
The Study of the Early Administration of Alendronate on Prevention of Bone Loss After Hip Fracture.
Started Jan 2003
10 enrolled
Osteoporosis
Career Relevance
No active career opportunities are currently linked to FOSAMAX PLUS D in available job markets, reflecting the product's mature, declining lifecycle stage. Professionals considering this product should evaluate stability risk against Merck's broader portfolio and long-term positioning in osteoporosis.
Company
Worked on FOSAMAX PLUS D at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.